Armata Pharmaceuticals, Inc. (ARMP)
NYSEAMERICAN: ARMP · Real-Time Price · USD
10.60
-0.36 (-3.28%)
At close: Mar 6, 2026, 4:00 PM EST
10.60
0.00 (0.00%)
After-hours: Mar 6, 2026, 8:00 PM EST
Armata Pharmaceuticals Employees
Armata Pharmaceuticals had 60 employees as of December 31, 2024. The number of employees decreased by 6 or -9.09% compared to the previous year.
Employees
60
Change (1Y)
-6
Growth (1Y)
-9.09%
Revenue / Employee
$84,233
Profits / Employee
-$781,683
Market Cap
385.91M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 60 | -6 | -9.09% | 60 | 0 |
| Dec 31, 2023 | 66 | -9 | -12.00% | 66 | 0 |
| Dec 31, 2022 | 75 | 4 | 5.63% | 72 | 3 |
| Dec 31, 2021 | 71 | 9 | 14.52% | 69 | 2 |
| Dec 31, 2020 | 62 | 24 | 63.16% | 59 | 3 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ginkgo Bioworks Holdings | 834 |
| Bicycle Therapeutics | 305 |
| Absci | 157 |
| Aura Biosciences | 109 |
| Niagen Bioscience | 104 |
| Keros Therapeutics | 82 |
| PureTech Health | 56 |
| Atea Pharmaceuticals | 56 |
ARMP News
- 11 days ago - Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02 - PRNewsWire
- 7 weeks ago - Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus - PRNewsWire
- 3 months ago - Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST - PRNewsWire
- 4 months ago - Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update - PRNewsWire
- 4 months ago - Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California - PRNewsWire
- 4 months ago - Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™ - PRNewsWire
- 5 months ago - Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™ - PRNewsWire
- 6 months ago - Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology - PRNewsWire